Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
27 studies found for:    " March 10, 2010":" April 09, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
Condition: HIV-1 Infection
Intervention: Drug: Bevirimat
22 Completed A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Condition: HIV-1 Infection
Interventions: Drug: TBR-652;   Drug: TBR-652 Matching Placebo;   Drug: TBR-652 50 mg;   Drug: TBR-652 75 mg;   Drug: TBR-652 100 mg;   Drug: TBR-652 150 mg
23 Active, not recruiting TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Condition: HIV-1 Infections
Interventions: Drug: Darunavir;   Drug: Ritonavir
24 Completed Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
Conditions: Acquired Immunodeficiency Syndrome;   Infant, Newborn;   Anemia;   Neutropenia;   HIV Infections
Intervention: Drug: cotrimoxazole
25 Completed
Has Results
Mesalamine to Reduce T Cell Activation in HIV Infection
Conditions: HIV Infections;   Sexually Transmitted Diseases;   Immune System Diseases;   Lentivirus Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Mesalamine (5-aminosalicylic acid, Apriso);   Drug: Placebo
26 Completed Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Condition: AIDS
Interventions: Procedure: Blood collection;   Biological: GSK HIV vaccine 732462
27 Suspended Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive;   Plasmablastic Lymphoma
Interventions: Drug: EPOCH-R;   Drug: EPOCH-RR

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-27) Next Page   
Study has passed its completion date and status has not been verified in more than two years.